PCSK9抑制剂降低脂蛋白a作用的研究进展

Reducing Lipoprotein( a) by PCSK9 Inhibitors

脂蛋白a被认为是心血管疾病的独立危险因素,目前临床上常用他汀类药物来控制脂蛋白a的水平,但结果并不理想。前蛋白转化酶枯草溶菌素9(PCSK9)是一种肝源性分泌蛋白并与脂蛋白a的水平呈正相关,新近完成的临床试验也显示PCSK9的抑制剂能有效降低脂蛋白a的水平。现探究在心血管疾病中PCSK9抑制剂对脂蛋白a的作用及机制,以进一步指导临床治疗。

Lipoprotein (a) is considered to be an independent risk factor for cardiovascular disease. Currently, statins are commonly used in clinical practice to control the level of lipoprotein (a), but the result is not ideal.Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a liver-derived secreted protein, and PCSK9 is positively correlated with the level of lipoprotein (a). Recent clinical trials have also shown that PCSK9 inhibitors can effectively reduce the level of lipoprotein (a). This article explores the role and mechanism of PCSK9 inhibitors on lipoprotein (a) in cardiovascular disease to further guide clinical treatment.